EMA-HTA Parallel Scientific Advice: Challenges and Opportunities
Conducting an EMA-HTA Parallel Scientific Advice for a Development Product between Clinical Phase I and Phase III
Autori
Viac o knihe
The book explores the differences between regulatory agencies and health technology assessment (HTA) bodies in evaluating new medicines. It highlights how HTA bodies require additional evidence for reimbursement decisions, which can vary by country and include factors like unmet medical needs and cost-effectiveness. The text discusses the challenges posed by the evidence gap between regulatory approval and reimbursement, which can delay patient access to new drugs. It emphasizes the importance of early collaboration among industry, regulatory authorities, and reimbursement agencies in the drug development process.
Nákup knihy
EMA-HTA Parallel Scientific Advice: Challenges and Opportunities, Ulrike Fuchs
- Jazyk
- Rok vydania
- 2017
- product-detail.submit-box.info.binding
- (mäkká)
Doručenie
Platobné metódy
Navrhnúť zmenu
- Titul
- EMA-HTA Parallel Scientific Advice: Challenges and Opportunities
- Podtitul
- Conducting an EMA-HTA Parallel Scientific Advice for a Development Product between Clinical Phase I and Phase III
- Jazyk
- anglicky
- Autori
- Ulrike Fuchs
- Vydavateľ
- AV Akademikerverlag
- Rok vydania
- 2017
- Väzba
- mäkká
- Počet strán
- 112
- ISBN13
- 9783330521254
- Kategórie
- Zdravie / Medicína / Lekárstvo
- Anotácia
- The book explores the differences between regulatory agencies and health technology assessment (HTA) bodies in evaluating new medicines. It highlights how HTA bodies require additional evidence for reimbursement decisions, which can vary by country and include factors like unmet medical needs and cost-effectiveness. The text discusses the challenges posed by the evidence gap between regulatory approval and reimbursement, which can delay patient access to new drugs. It emphasizes the importance of early collaboration among industry, regulatory authorities, and reimbursement agencies in the drug development process.